An interventional study of Catheter ablation using pulsed field ablation and Catheter ablation using cryoballoon ablation in Persistent Atrial Fibrillation, sponsored by Kitasato University. Recruiting at 1 site in Japan. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-08-26.
Sponsored by Kitasato University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Atrial Fibrillation with a site in Japan — 7 open to participants now, 13 under way, 3 of them phase 3. Atrial Fibrillation · Japan.
Among the 84 studies in Atrial Fibrillation with a site in Japan, this one is the 35th largest by planned enrollment of the 55 interventional ones that give a count, is one of 3 that started in 2025, is one of 16 with no phase, reaches primary completion later than 6 of the 12 other live ones, and was the 80th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →7 of the 84 studies in Atrial Fibrillation with a site in Japan are open now. Recruiting first, the newest first:
Oslo University Hospital · Sites in Japan, United States, Belgium and 7 more countries
Ages 18+
Regeneron Pharmaceuticals · Sites in Japan, United States, Canada
Ages 18+
OCEAN-SHD Study Group · Sites in Japan
Anthos Therapeutics, Inc. · Sites in Japan, United States, Argentina and 32 more countries
Ages 65+
Diagram B.V. · Sites in Japan, France, Netherlands
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 15 · Phase 4 10
First in 2004; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 500 across the 55 interventional studies, 5,000 across the 29 observational. Of the 61 that completed or were terminated, 36 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 84 have an industry lead sponsor. The 10 most frequent:
Kitasato University is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Kitasato University has 2 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
3 of the studies in Atrial Fibrillation with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07870837iRhythm Technologies, Inc.Head-to-Head (H2H) Comparison of Ambulatory Cardiac ECG Monitors in Japan | 2027-03-31 |
| NCT04428944McGill University Health Centre/Research Institute of the McGill University Health CentreSTrategies for Catheter Ablation of peRsistent Atrial Fibrlllation | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 84 studies in Atrial Fibrillation with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical study is being conducted to compare two different treatment methods for persistent atrial fibrillation (AF), a common heart rhythm disorder. Atrial fibrillation occurs when the upper chambers of the heart (the atria) beat rapidly and irregularly. This can lead to symptoms like palpitations, shortness of breath, or fatigue, and it increases the risk of stroke or heart failure.
Persistent atrial fibrillation means that the irregular heart rhythm continues and does not stop on its own. Treatment often includes a procedure called catheter ablation, where special instruments are used to create small scars in the heart to block the abnormal electrical signals causing the arrhythmia.
Currently, two main types of catheter ablation are used in Japan:
Cryoballoon Ablation: A technique that uses extreme cold to create scars and isolate the pulmonary veins, which are often the source of the irregular signals.
Pulsed Field Ablation (PFA): A newer technique that uses very short bursts of electrical energy to target the heart tissue, with the aim of reducing damage to surrounding structures.
While pulsed field ablation has been introduced in Japan recently and seems to be safe, there is limited data about how well it works compared to cryoballoon ablation, especially in patients with persistent atrial fibrillation. This study aims to find out whether pulsed field ablation is as effective and safe as cryoballoon ablation for treating persistent AF.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The PFA group includes persistent AF patients treated with PFA
Device: Catheter ablation using pulsed field ablation
The CBA group includes persistent AF patients treated with CBA
Device: Catheter ablation using cryoballoon ablation
PulseSelect™ Pulsed Field Ablation System: This intervention uses the PulseSelect™ system to perform pulsed field ablation (PFA) for pulmonary vein isolation in patients with persistent atrial fibrillation. PFA delivers short, high-voltage electrical pulses that selectively affect myocardial cells while minimizing damage to surrounding tissues such as the esophagus or phrenic nerve. This technique is designed to reduce procedural complications and improve safety compared to traditional thermal ablation methods.
Cryoballoon Ablation: This intervention uses a cryoballoon catheter to perform pulmonary vein isolation by freezing tissue around the pulmonary veins. The balloon delivers extreme cold temperatures to create transmural lesions that block abnormal electrical signals responsible for atrial fibrillation. Cryoballoon ablation is widely used and considered effective for atrial fibrillation treatment but may carry risks related to collateral tissue injury.
Freedom from atrial fibrillation recurrence at 12 months
Proportion of patients without documented atrial fibrillation lasting 30 seconds or longer after a 3-month blanking period following the ablation procedure, assessed by ECG or Holter monitoring.
Time frame: 12 months post-procedure
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 30 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kitasato University